Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ ICU admission -43% Improvement Relative Risk HCQ for COVID-19  Küçükakkaş et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 17 patients in Turkey Study underpowered to detect differences c19hcq.org Küçükakkaş et al., Research Square, Jul 2021 Favors HCQ Favors control

The effect of hydroxychloroquine against SARS-CoV-2 infection in rheumatoid arthritis patients

Küçükakkaş et al., Research Square, doi:10.21203/rs.3.rs-43812/v1
Jul 2021  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 17 rheumatoid arthritis COVID-19+ patients, 7 on HCQ treatment, showing no significant differences. They study reports only including hospitalized patients, but the results include non-hospitalized patients. Results do not reflect potential difference in the probability that a case is serious enough to have been tested and identified. Few group details are provided (even the age of patients in each group is not specified). This study is excluded in the after exclusion results of meta analysis: minimal details of groups provided.
risk of ICU admission, 42.9% higher, RR 1.43, p = 1.00, treatment 1 of 7 (14.3%), control 1 of 10 (10.0%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Küçükakkaş et al., 20 Jul 2021, retrospective, Turkey, preprint, 2 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
The effect of hydroxychloroquine against SARS-CoV-2 infection in rheumatoid arthritis patients
Okan Küçükakkaş, Teoman Aydın
doi:10.21203/rs.3.rs-43812/v1
INTRODUCTION: The effectiveness of hydroxychloroquine in SARS-CoV-2 prophylaxis and treatment is still controversial. In this study, our aim is to investigate the potential effects of hydroxychloroquine therapy on patients with diagnosed with rheumatoid arthritis and a con rmed SARS-CoV-2 infection. METHOD: We included patients who were followed up with a diagnosis of rheumatoid arthritis and whose SARS-CoV-2 infection was con rmed. The patients were divided into two groups as those who previously used hydroxychloroquine and those who did not, and were compared in terms of clinical and laboratory data. RESULTS: Our study included 17 patients with adequate data (2 males, 15 females). The mean age of the patients was 57.2 ± 11.6 years. 7 (41.2%) patients were receiving hydroxychloroquine regularly for the last 6 months. When the effect of hydroxychloroquine on clinical and laboratory parameters of patients was examined, there was no signi cant difference between the groups of patients using and not using hydroxychloroquine. The patients using and not using hydroxychloroquine were compared for the presence of typical SARS-CoV-2 infection ndings on computed tomography images, admission to the hospital and intensive care. No signi cant differences were observed between these two groups. CONCLUSIONS: Many studies on the effectiveness of hydroxychloroquine use in SARS-CoV-2 infection are still ongoing. Due to its importance in rheumatology practice, it is very important to clarify the position of hydroxychloroquine in SARS-CoV-2 therapy. Our ndings suggest that having previously used hydroxychloroquine does not have any negative or positive effect on the infection.
Declarations Compliance with ethical standards Disclosures: None. Financial support received for the study: None. Ethical approval: Approval has been received by the Institutional Review Board. Competing interests: The declare no competing interests. A statement on participant consent: Ethical was obtained from the institutional ethical committee and no patient consent form was required due to the use of retrospective data.
References
Alia, Jm, Does hydroxychloroquine combat COVID-19? A timeline of evidence, J Am Acad Dermatol
Ben-Zvi, Kivity, Langevitz, Shoenfeld, Hydroxychloroquine: From malaria to autoimmunity, Clin Rev Allergy Immunol
Blumentals, Arreglado, Napalkov, Toovey, Rheumatoid arthritis and the incidence of in uenza and in uenza-related complications: a retrospective cohort study, BMC Musculoskelet Disord
Boulos, Rolain, Raoult, Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells, Antimicrob Agents Chemother
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to ght COVID-19, Int J Antimicrob Agents
Cortegiani, Ingoglia, Ippolito, Giarratano, Einav, A systematic review on the e cacy and safety of chloroquine for the treatment of COVID-19, J Crit Care, doi:10.1016/j.jcrc.2020.03.005
Dahly, Gates, Morris, Statistical review of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial, Zenodo, doi:10.5281/zenodo.3724167
Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105938
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent e cacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Kapoor, Kapoor, Role of chloroquine and hydroxychloroquine in the treatment of COVID-19 infection: a systematic literature review, medRxiv, doi:10.1101/2020.03.24.20042366
Listing, Gerhold, Zink, The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment, Rheumatology
Michaud, Wip Er, Shaw, Simon, Cornish et al., Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic, ACR Open Rheumatol
Owens, Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology, Lancet Rheumatol, doi:10.1016/S2665-9913(20)30089-8
Padmanabhan, Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with nitazoxanide and hydroxychloroquine, doi:10.13140/RG.2.2.28124.74882
Raoult, Drancourt, Vestris, Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells, Antimicrob Agents Chemother
Raoult, Houpikian, Tissot, Riss, Arditi-Djiane et al., Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and o oxacin or hydroxychloroquine, Arch Intern Med, doi:10.1001/archinte.159.2.167
Rolain, Colson, Raoult, Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infection in the 21st century, Int J Antimicrob Agents
Sinha, Balayla, Hydroxychloroquine and covid-19, Postgrad Med J, doi:10.1136/postgradmedj-2020-137785
Song, Kang, Choi, Seo, Lee et al., Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional diseasemodifying antirheumatic drugs, Rheumatol Int
Song, Kang, Choi, Seo, Lee et al., Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional diseasemodifying antirheumatic drugs, Rheumatol Int
Touret, De Lamballerie, Of chloroquine and COVID-19, Antiviral Res, doi:10.1016/j.antiviral.2020.104762
Vinogradova, Hippisley-Cox, Coupland, Identi cation of new risk factors for pneumonia: population-based casecontrol study, Br J Gen Pract
Vinogradova, Hippisley-Cox, Coupland, Identi cation of new risk factors for pneumonia: population-based casecontrol study, Br J Gen Pract
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wu, Chang, Kor, Yang, Chiu et al., Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis, Clin J Am Soc Nephrol
Xie, Wang, Zhang, Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217556
Yao, Ye, Zhang, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
Yazdany, Kim, Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know, Ann Intern Med
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit